Education
About Us
Working with TipRanks
Follow Us
Treace Medical Concepts (TMCI)
NASDAQ:TMCI
TMCI Stock Chart & Stats
$1.47
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.47
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.41 - $9.56
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$101.41M
Enterprise Value$96.94M
Total Cash (Recent Filing)$48.37M
Total Debt (Recent Filing)$13.98M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 13, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding64,590,500
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit0.57
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$3.56Price Target Upside142.35% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$210.29M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently ~80% gross margins provide durable product-level profitability, enabling Treace to fund R&D and sales investments while absorbing SG&A as scale grows. High margins create structural operating leverage potential if revenue stabilizes, improving path to sustainable profitability.
Expanding Product Portfolio And TAMMultiple new system launches materially expand the addressable market and product mix, providing a durable growth lever. Broader portfolio enables penetration into adjacent procedures, supports upsell of higher-ASP implants, and reduces single-product dependency over the medium term.
Growing Surgeon Adoption BaseA tripling of the active surgeon base creates network effects and recurring per-procedure demand. Rising adoption and training momentum increase procedural share, enhance stickiness of Lapiplasty ecosystem, and make future launches likelier to scale, supporting durable revenue streams.
Bears Say
Persistent Operating Losses & Negative FCFSustained operating losses and negative free cash flow force ongoing external financing or draw on credit, limiting financial flexibility. Until operating margins convert positive or FCF turns sustainably positive, the company faces structural funding risk and constrained reinvestment capacity.
2026 Guidance: Flat-to-declining Revenue And EBITDA LossManagement's guidance signals limited near-term growth and continued adjusted EBITDA losses, implying weak operational leverage. This reduces visibility into durable profitability, raises dependency on future product launches for recovery, and constrains the company's ability to deleverage organically.
Product Mix Shift And Market SoftnessA structural shift to lower‑ASP product mix and softness in elective procedures compresses average revenue per case and limits top-line recovery. If mix and procedure volumes remain muted, scale benefits from high-margin implants will be delayed, pressuring long-term margin expansion.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.41 and its highest was $9.56 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $101.41M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is May 13, 2026 which is in 68 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on Feb 27, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.002.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.31.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,590,500 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went down -11.429%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.56 (142.35% Upside)
$3.56 (142.35% Upside)
Blogger Sentiment
Bullish
TMCI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 120.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-51.63%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
TMCI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: the company demonstrated meaningful operational progress — expanding its product portfolio, accelerating surgeon adoption, materially reducing cash burn and improving full-year adjusted EBITDA vs prior year — and secured liquidity. However, these positives are offset by near-term revenue pressure driven by a mix shift toward lower-priced products, market softness in elective foot and ankle procedures, a sizable Q4 GAAP net loss increase, and guidance that implies flat-to-declining revenue for 2026 with an expectation of an adjusted EBITDA loss. Management expects improvements later in 2026 (stronger Q3/Q4) as new higher-ASP products launch and adoption deepens, but the current outlook and recent quarterly results temper the outlook.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$3.56
▲(142.35% Upside)
Technical Analysis
Ownership Overview
29.58% Insiders
12.33% Mutual Funds
13.61% Other Institutional Investors
36.94% Public Companies and
Individual Investors